No Data
China Post Securities: ADC drug innovation drives development, and the industry's high prosperity continues.
Several varieties with sales amounts reaching tens of billions of yuan are expected to emerge in the domestic ADC drug field, with many biopharmaceutical and biotechnology companies focused on layout. It is recommended to actively pay attention to pharmaceutical companies with smooth clinical progress and overseas prospects.
One Lepu Biopharma Insider Has Reduced Their Stake
Why We're Not Concerned Yet About Lepu Biopharma Co., Ltd.'s (HKG:2157) 26% Share Price Plunge
Changes in Hong Kong stocks | Lepu Bio-B (02157) is now up more than 8%. The company has released a number of research results and recently raised funds for ADC candidate product development
Lepu Bio-B (02157) is now up more than 8%. As of press release, it has risen 7.83% to HK$4.82, with a turnover of HK$28.239,500.
Lepu Bio-B (02157.HK) successfully placed 51.17 million shares to raise HK$230 million
On May 24, GLONGHUI | Lepu Bio-B (02157.HK) announced that all conditions of the placement matters contained in the placement agreement (including (including) approval by the Listing Committee for the listing and trading of the placement shares) have been met, and that the placement was completed on May 24, 2024. The company has successfully placed a total of 51.17 million shares at the placement price of HK$4.58 per share to no less than six undertakers, accounting for about 3.09% and 2.99% of all issued H shares and all issued shares after the expansion of the allotted shares issued and issued, respectively. Total proceeds from placement transactions and proceeds
Lepu Biopharma to Present Three Studies During US Cancer Meet; Shares Dip 7%
No Data
